US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

49.28

-0.1000-0.20%

Post-market: 49.280.00000.00%19:30 EDT

Volume:381.48K

Turnover:18.76M

Market Cap:15.07B

PE:22.10

High:49.32

Open:48.96

Low:48.66

Close:49.38

52wk High:55.49

52wk Low:45.78

Shares:305.78M

Float Shares:305.78M

Volume Ratio:1.45

T/O Rate:0.12%

Dividend:2.09

Dividend Rate:4.24%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.63

PE(LYR):19.99

Loading ...

Overview Company News Filings

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program

Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease

Actinogen Medical Reaches Common Understanding With European Regulator on Pathway to Marketing Approval for Alzheimers' Disease Program

MT Newswires Live

Suzhou Ribo Seeks Coronary Artery Disease Drug Trial in Europe

MT Newswires Live

Suzhou Ribo Advances CAD siRNA Drug With EMA Phase II Filing

AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Press Release: MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026

Shanghai Henlius Biotech (SEHK:2696) Valuation Check After Positive EMA CHMP Opinion For Serplulimab

Simply Wall St.

AbbVie’s EMA Wins For Boey And MAVIRET Expand European Growth Story

Simply Wall St.

Henlius Wins Key EMA Backing for Serplulimab Lung Cancer Use

MedinCell: EMA Acceptance and 2026 U.S. Approval Outlook for Olanzapine LAI Underpin Reiterated Buy and €33 Price Target

Teva announces EMA acceptance of MAA for olanzapine long-acting injectable

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

Press Release: Hemab Therapeutics Reports First Quarter 2026 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/EMA/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":49.28,"timestamp":1789761600000,"preClose":49.38,"halted":0,"volume":381479,"hourTrading":{"tag":"盘后","latestPrice":49.28,"preClose":49.28,"latestTime":"19:30 EDT","volume":40384,"amount":1992699.06912,"timestamp":1789774206298,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0020251113811259906,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Market Closed","change":-0.1,"latestTime":"09-18 16:00:00 EDT","open":48.96,"high":49.32,"low":48.66,"amount":18759191.6771,"amplitude":0.013366,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":49.38,"dividendRate":0.042791,"postHourTrading":{"tag":"盘后","latestPrice":49.28,"preClose":49.28,"latestTime":"19:30 EDT","volume":40384,"amount":1992699.06912,"timestamp":1789774206298,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.4540410074543813,"impliedVol":0.4231,"impliedVolPercentile":0.9761},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":1.4540410074543813,"shares":305783111,"dividePrice":2.087723,"high":49.32,"amplitude":0.013366,"preClose":49.38,"low":48.66,"week52Low":45.78,"pbRate":"1.63","psRate":"2.36","week52High":55.49,"institutionHeld":0,"latestPrice":49.28,"eps":2.229761,"divideRate":0.042365,"volume":381479,"delay":0,"ttmEps":2.229761,"open":48.96,"prevYearClose":49.24,"prevWeekClose":49.19,"prevMonthClose":50.09,"prevQuarterClose":53.02,"fiveDayClose":49.19,"twentyDayClose":51.78,"sixtyDayClose":52.9,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-09-18","current":22.101023,"percent":0.558282,"low":16.637027,"twenty":17.871551,"median":20.245144,"eighty":21.031403,"high":22.07626,"avg":19.830871,"sd":1.467509,"marketCap":15149228130.36},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-11","current":20.227938,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"marketCap":15223834714.33},{"date":"2026-09-18","current":20.381538,"twenty":17.871551,"median":20.245144,"eighty":21.031403,"marketCap":15149228130.36}],"updateTime":1789894305969},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640938168","title":"Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2640938168","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640938168?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:25","pubTimestamp":1780579500,"startTime":"0","endTime":"0","summary":"Company identifies real estate, digital assets, and marketable securities, among others, as potential sources of liquidity — with a combined value of approximately $20 millionProceeds could fund a mea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/04/3306858/0/en/Cosmos-Health-Identifies-Approximately-20-Million-in-Non-Core-Assets-Available-for-Monetization-to-Accelerate-Growth-and-Unlock-Shareholder-Value.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COSM","BK4175","EMA","BK4081","AAQC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951227","title":"Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951227","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951227?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:25","pubTimestamp":1780316700,"startTime":"0","endTime":"0","summary":"CHICAGO, June  01, 2026  (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the exte","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304348/0/en/Cosmos-Health-Enters-69-Billion-Global-Animal-Health-Industry-with-Veterinary-C-Scrub-Wash-4-Following-Successful-European-Standard-Testing-Under-EN-1656-and-EN-1657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COSM","EMA","SMP","BK4175","BK4124","EPV","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640989428","title":"Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989428","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640989428?lang=en_us&edition=fundamental","pubTime":"2026-06-01 07:30","pubTimestamp":1780270200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  31, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303964/0/en/Ascentage-Pharma-Presents-Data-on-Olverembatinib-in-CML-LBP-and-Ph-BCP-ALL-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1699723380.USD","ALL","LU2355687059.USD","BK4139","BK4161","BK4107","BK4533","CR","AAPG","LU0985320562.USD","LU1571399168.USD","EMA","BK4081","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640989426","title":"Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989426","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640989426?lang=en_us&edition=fundamental","pubTime":"2026-06-01 07:30","pubTimestamp":1780270200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  31, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303966/0/en/Ascentage-Pharma-Presents-Updated-Clinical-Data-for-Olverembatinib-as-Second-Line-Therapy-in-CML-CP-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1261432733.SGD","BK4588","EMA","CP","AAPG","BK4585","BK4139","BK4016","BK4081","LU1989763690.USD","LU1989763427.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698491","title":"Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698491","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698491?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969600,"startTime":"0","endTime":"0","summary":"XanaMIA randomized, pivotal trial of oral Xanamem 10 mg fully enrolled and remains on track for topline final results in November 2026SYDNEY, May  28, 2026  (GLOBE NEWSWIRE) -- Actinogen Medical Limit","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302808/0/en/Actinogen-receives-positive-EMA-scientific-advice-aligned-with-prior-FDA-guidance-for-its-Alzheimer-s-disease-program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4081","EMA","AD","BK4132","LABU","BK4156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638656566","title":"Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2638656566","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638656566?lang=en_us&edition=fundamental","pubTime":"2026-05-28 10:43","pubTimestamp":1779936180,"startTime":"0","endTime":"0","summary":"Coronary artery disease  remains a leading cause of morbidity and mortality globally, driven by atherosclerotic plaque formation and associated thrombotic complications such as myocardial infarction and other ischemic events. Despite the widespread use of standard of care therapies, including antiplatelet and anticoagulant therapies, a substantial residual risk of thrombotic events remains in patients with stable CAD, even when treated with optimized treatment. Current therapies are further limited by an increased risk of bleeding, restricting their intensity and long-term use in many patients. Consequently, there is a significant unmet medical need for novel antithrombotic approaches that can provide effective and sustained protection against thrombosis while maintaining a favorable safety profile, particularly with respect to bleeding risk.\"We are very pleased to advance our anti-thrombotic siRNA programs into the next stage of clinical development in Europe. This milestone reflects ","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ribo-announces-phase-2-clinical-trial-submission-to-ema-further-advancing-sirna-therapeutics-in-thromboembolic-disease-302783857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CAD.AU","BK4539","EMA","BK4081","BK7095","BK7504","CTA","BK4007","EMA.AU","BK7129","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638653254","title":"Actinogen Medical Reaches Common Understanding With European Regulator on Pathway to Marketing Approval for Alzheimers' Disease Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2638653254","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638653254?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:53","pubTimestamp":1779933233,"startTime":"0","endTime":"0","summary":"Actinogen Medical  reached a common understanding of the pathway to marketing approval for its Alzheimer's disease program in its scheduled scientific advice meeting with the European Medicines Agency , according to a Thursday Australian bourse filing.The understanding includes the specification of regulatory starting materials for the commercial manufacturing of Xanamem  drug substance, design considerations for an additional pivotal clinical trial, as well as the limited number of ancillary clinical pharmacology trials and nonclinical studies required.The understandings also include ensuring the proposed makeup of the planned safety database is consistent with EMA and US Food and Drug Administration  guidelines.The firm said the understandings align closely with the guidance received at an earlier meeting with the US FDA's Neurology-I division.Actinogen Medical's shares rose nearly 3% in recent trading on Thursday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACW.AU","BK7129","BK7067","EMA.AU","BK7508","EPV","BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638653364","title":"Suzhou Ribo Seeks Coronary Artery Disease Drug Trial in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2638653364","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638653364?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:33","pubTimestamp":1779932024,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for RBD1119 at the European Medicines Agency (EMA), according to a Thursday filing with the Hong Kong bourse.The trial aims to study the drug for the treatment of coronary artery disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA","BK4081","BK1161","06938","BK7129","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638342006","title":"Suzhou Ribo Advances CAD siRNA Drug With EMA Phase II Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638342006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638342006?lang=en_us&edition=fundamental","pubTime":"2026-05-28 06:57","pubTimestamp":1779922637,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. Class H ( ($HK:6938) ) just unveiled an announcement. Suzhou Ribo Life Science Co., Ltd. has advanced its cardio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-cad-sirna-drug-with-ema-phase-ii-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-cad-sirna-drug-with-ema-phase-ii-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638168897","title":"AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration","url":"https://stock-news.laohu8.com/highlight/detail?id=2638168897","media":"GlobeNewswire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638168897?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:47","pubTimestamp":1779886020,"startTime":"0","endTime":"0","summary":"Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual Inve","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301981/29489/en/AIM-ImmunoTech-Announces-Emerging-Ebola-Opportunity-for-Ampligen-Amid-Escalating-Global-Health-Concerns-and-WHO-Emergency-Declaration.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4081","AIM","EMA","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638021595","title":"BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9","url":"https://stock-news.laohu8.com/highlight/detail?id=2638021595","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638021595?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:30","pubTimestamp":1779881400,"startTime":"0","endTime":"0","summary":"- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for tr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301817/0/en/BridgeBio-Announces-FDA-Acceptance-and-Priority-Review-of-NDA-for-BBP-418-for-LGMD2I-R9.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","LABU","BK4588","EMA","BK4585","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638504968","title":"MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2638504968","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638504968?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:00","pubTimestamp":1779879600,"startTime":"0","endTime":"0","summary":"EscharEx Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue gu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301772/30505/en/MediWound-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIC","BK4081","BK4007","MDWD","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638549272","title":"Press Release: MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638549272","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638549272?lang=en_us&edition=fundamental","pubTime":"2026-05-27 01:00","pubTimestamp":1779814800,"startTime":"0","endTime":"0","summary":"--  In May 2026, the Company was informed of a \"negative trend\". opinion on its Marketing Authorization Application from the. Committee for Medicinal Products for Human Use  of the. European Medicines Agency , ahead of the expected CHMP formal. vote in June; the Company plans to request a re-examination. --  EBMT 2026 annual congress: MaaT Pharma presented data from the. pivotal ARES trial of MaaT013  featured in the. --  Revenues of EUR0.8 million in the first quarter of 2026 derived from. \"During the first quarter of 2026, we continued to execute with financial discipline while supporting the advancement of our clinical and regulatory priorities. The drawdown of EIB Tranche B, combined with ongoing operational optimization, has extended our cash runway into November 2026 supporting the upcoming regulatory steps, including the planned re-examination of the Marketing Authorization Application for MaaT013 ,\" stated Eric Soyer, CFO of MaaT Pharma.Europe to Clinigen, allowing MaaT Pharma ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","03160","CHMP","R","BK4588","LU1989772840.SGD","BK4162","BK4081","LU1291159041.SGD","BK4099","LU1989772923.USD","LU1496350502.SGD","BK4232","EMA","MET","BK4022","TM","BK4087","LU1989771016.USD","BK4585","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638515769","title":"Shanghai Henlius Biotech (SEHK:2696) Valuation Check After Positive EMA CHMP Opinion For Serplulimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2638515769","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638515769?lang=en_us&edition=fundamental","pubTime":"2026-05-26 17:25","pubTimestamp":1779787526,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (SEHK:2696) is back on investors’ radar after winning a positive opinion from the EMA’s CHMP for serplulimab plus chemotherapy in first-line advanced squamous non-small cell lung cancer in Europe.\nSee our latest analysis for Shanghai Henlius Biotech.\nDespite the positive CHMP opinion and a series of product updates, Shanghai Henlius Biotech’s short term share price return has come under pressure, with the 1 month share price return down 17.22%. However, the 1 year...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-valuation-check-after-posi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-valuation-check-after-posi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CHMP","EMA","HK0000320223.HKD","DCF","HK0000306701.USD","HK0000320264.USD","BK4585","HK0000165453.HKD","HK0000306685.HKD","BK4581","XBI","02696","BK1161","BK4588","BK4087","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637223372","title":"AbbVie’s EMA Wins For Boey And MAVIRET Expand European Growth Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2637223372","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637223372?lang=en_us&edition=fundamental","pubTime":"2026-05-24 11:25","pubTimestamp":1779593131,"startTime":"0","endTime":"0","summary":"AbbVie (NYSE:ABBV) received positive European Medicines Agency opinions for Boey®, its new aesthetics product.\nThe EMA also issued a favorable opinion for MAVIRET®, AbbVie’s oral hepatitis C therapy.\nThese opinions cover up to 30 European countries and precede potential regulatory approvals and launches.\n\nAbbVie enters this regulatory milestone with its stock at $215.7 and a return of 21.5% over the past year. Over the past three years the stock is up 74.6% and over five years it is up...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvies-ema-wins-for-boey-and-maviret-expand-european-growth","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvies-ema-wins-for-boey-and-maviret-expand-european-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1037948541.HKD","EPV","LU2237443382.USD","LU0943347566.SGD","LU2129689431.USD","LU1983299246.USD","LU1244550221.USD","LU0965509283.SGD","SG9999003800.SGD","LU0057025933.USD","LU0795875169.SGD","LU0985320562.USD","LU2468319806.SGD","LU0310799852.SGD","IE00BN8TJ469.HKD","LU0029864427.USD","LU0823416689.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU0114720955.EUR","IE0000B7K699.USD","IE0009355771.USD","LU2089283258.USD","LU0320765646.SGD","BK4566","LU0912757837.SGD","SG9999001440.SGD","LU0965509101.SGD","BK4559","LU1244550577.SGD","IE0004445239.USD","LU2023251221.USD","LU0708994859.HKD","BK4588","IE00BBT3K403.USD","EMA","LU1934455863.HKD","LU2237443465.HKD","LU0234572021.USD","LU0158827948.USD","IE000SO60NU8.SGD","LU2237443895.HKD","LU2347655156.SGD","IE00B19Z3B42.SGD","SG9999015945.SGD","LU1162221912.USD","LU0456855351.SGD","LU2237443978.SGD","ABBV","LU1003077747.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637310480","title":"Henlius Wins Key EMA Backing for Serplulimab Lung Cancer Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2637310480","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637310480?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:10","pubTimestamp":1779459017,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ). Shanghai Henlius Biotech said its anti-PD-1 monoclonal a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/henlius-wins-key-ema-backing-for-serplulimab-lung-cancer-use?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/henlius-wins-key-ema-backing-for-serplulimab-lung-cancer-use?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","XBI","BK4588","EMA","BK4081","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637392068","title":"MedinCell: EMA Acceptance and 2026 U.S. Approval Outlook for Olanzapine LAI Underpin Reiterated Buy and €33 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2637392068","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637392068?lang=en_us&edition=fundamental","pubTime":"2026-05-22 16:55","pubTimestamp":1779440119,"startTime":"0","endTime":"0","summary":"Oscar Haffen Lamm, an analyst from Stifel Nicolaus, reiterated the Buy rating on MedinCell SA. The associated price target is €33.00. Oscar Haffen ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/medincell-ema-acceptance-and-2026-u-s-approval-outlook-for-olanzapine-lai-underpin-reiterated-buy-and-e33-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/medincell-ema-acceptance-and-2026-u-s-approval-outlook-for-olanzapine-lai-underpin-reiterated-buy-and-e33-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637235353","title":"Teva announces EMA acceptance of MAA for olanzapine long-acting injectable","url":"https://stock-news.laohu8.com/highlight/detail?id=2637235353","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637235353?lang=en_us&edition=fundamental","pubTime":"2026-05-22 00:35","pubTimestamp":1779381337,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceuticals International announced that the European Medicines Agency has accepted the Marketing Authorization Application for ola...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-ema-acceptance-of-maa-for-olanzapine-long-acting-injectable-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-ema-acceptance-of-maa-for-olanzapine-long-acting-injectable-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4557","BK4588","EMA","BK4007","BK4215","BK4596","BK4566","EPV","LU1983299246.USD","BK4559","BK4081","TEVA","BK4584","LU2324357040.USD","MAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637353639","title":"The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2637353639","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637353639?lang=en_us&edition=fundamental","pubTime":"2026-05-22 00:30","pubTimestamp":1779381000,"startTime":"0","endTime":"0","summary":"The olanzapine long-acting injectable (TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.If approved, TEV-‘749 could help fill a ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299597/0/en/The-European-Medicines-Agency-Accepts-Teva-s-Marketing-Authorization-Application-for-Olanzapine-Long-Acting-Injectable-TEV-749-for-the-Treatment-of-Schizophrenia-in-Adults.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAA","EMA","EPV","BK4585","BK4081","MDCO","BK4588","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637638701","title":"Press Release: Hemab Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2637638701","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637638701?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:00","pubTimestamp":1779361200,"startTime":"0","endTime":"0","summary":"Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq. Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia. CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 21, 2026  -- Hemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced financial results for the first quarter ended March 31, 2026 and noted recent business highlights.\"As a public company we continue our journey to accelerate progress and broaden impact for people living with serious coagulation disorders with strong momentum across our clinical programs,\" said Benny Srensen, Chief Executive Officer of Hemab Therapeutics. \"The Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia recognizes both the potential for sutacimig to address a significant unmet need, and the urgency of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","COAG","BK4588","GT","LENZ","EMA","BK4119","BK4081","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}